Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard M Stone

Showing results (131-140 of 420) with videos related to

Pageof 42
Sort By:
Leukemia & Lymphoma|March 5, 2003
Quantitative monitoring of BCR/ABL transcript during STI-571 therapyCatherine J Wu, Donna Neuberg, Antoinette Chillemi, et al.
Investigational New Drugs|May 24, 2013
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)Pankaj Gupta, Flora Mulkey, Robert P Hasserjian, et al.
American Journal of Hematology|April 10, 2021
Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following inductionJ Erika Haydu, Yael Flamand, Rahul S Vedula, et al.
Haematologica|September 23, 2021
Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignanciesClark DuMontier, Hajime Uno, Tammy Hshieh, et al.
Blood|March 9, 2007
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801Daniel J DeAngelo, Daohai Yu, Jeffrey L Johnson, et al.
Blood|May 10, 2003
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantationMartha Wadleigh, Paul G Richardson, David Zahrieh, et al.
American Journal of Hematology|June 1, 2019
High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemiaSanjay S Patel, Geraldine S Pinkus, Lauren L Ritterhouse, et al.
Cancer|October 6, 2018
Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutionsDavid P Steensma, Andrew M Brunner, Amy E DeZern, et al.
Cancer|November 26, 2008
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803)David L Grinblatt, Daohai Yu, Vera Hars, et al.
Blood|October 2, 2004
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of ageEdwin P Alyea, Haesook T Kim, Vincent Ho, et al.
Pageof 42

Showing results (131-140 of 420) with videos related to

Sort By:
Pageof 42
Leukemia & Lymphoma|March 5, 2003
Quantitative monitoring of BCR/ABL transcript during STI-571 therapyCatherine J Wu, Donna Neuberg, Antoinette Chillemi, et al.
Investigational New Drugs|May 24, 2013
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)Pankaj Gupta, Flora Mulkey, Robert P Hasserjian, et al.
American Journal of Hematology|April 10, 2021
Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following inductionJ Erika Haydu, Yael Flamand, Rahul S Vedula, et al.
Haematologica|September 23, 2021
Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignanciesClark DuMontier, Hajime Uno, Tammy Hshieh, et al.
Blood|March 9, 2007
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801Daniel J DeAngelo, Daohai Yu, Jeffrey L Johnson, et al.
Blood|May 10, 2003
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantationMartha Wadleigh, Paul G Richardson, David Zahrieh, et al.
American Journal of Hematology|June 1, 2019
High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemiaSanjay S Patel, Geraldine S Pinkus, Lauren L Ritterhouse, et al.
Cancer|October 6, 2018
Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutionsDavid P Steensma, Andrew M Brunner, Amy E DeZern, et al.
Cancer|November 26, 2008
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803)David L Grinblatt, Daohai Yu, Vera Hars, et al.
Blood|October 2, 2004
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of ageEdwin P Alyea, Haesook T Kim, Vincent Ho, et al.
Pageof 42